Russia says unnamed U.S. firm violated patent rights on Sputnik V vaccine

Health News
FILE PHOTO: Vials labelled “Sputnik V Coronavirus COVID-19 Vaccine” and a syringe are seen in front of a displayed Sputnik V logo, in this illustration photo taken March 12, 2021. REUTERS/Dado Ruvic/Illustration

MOSCOW (Reuters) – Russia’s RDIF sovereign wealth fund said on Monday a U.S. firm had violated Russian patent rights on its Sputnik V vaccine against COVID-19.

RDIF, which actively markets Sputnik V abroad, did not disclose the name of the U.S. firm.

Source: Read Full Article

Related posts:
  1. Singapore becomes first in Asia to approve Moderna's COVID-19 vaccine
  2. To sell or swap? South Africa weighs options for AstraZeneca shots ahead of J&J rollout
  3. Nepal approves Chinese COVID-19 vaccine Vero Cell for emergency use